CRDF Q3'26 Earnings: EPS estimate is (0.14) USD

What happened

Cardiff Oncology is set to announce its Q3'26 results on October 29 at 8:00 AM ET. The revenue estimate is 81.43 thousand USD, and the EPS (earnings per share) estimate is (0.14) USD.

Confirmed

Global impact / market context

An expected loss means the company is forecast to spend more than it earns. Revenue of only 81.43 thousand USD is small, so investors will likely focus on cash use and how long funding lasts.

Analyst inference

Recent quarters show uneven revenue and repeated losses. That pattern suggests results depend on a few payments, so a single quarter's revenue may not signal a lasting trend for the business.

Analyst inference

What to watch

1. Watch whether reported revenue matches the 81.43 thousand USD estimate and whether EPS matches the (0.14) USD estimate when Cardiff Oncology reports on October 29. Confirmed
2. Watch for company guidance on research spending and cash available, which means money on hand to fund operations, since continued losses could raise the need for new funding. Proposed
3. Watch whether revenue stays near the low end seen in past quarters, since weak and uneven revenue would put more pressure on costs and on the company's funding position. Analyst inference

Evidence

• Original source link unavailable